Repligen Co. (NASDAQ:RGEN) Shares Sold by Total Clarity Wealth Management Inc.

Total Clarity Wealth Management Inc. lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 4.9% in the second quarter, HoldingsChannel.com reports. The firm owned 2,940 shares of the biotechnology company’s stock after selling 150 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Repligen were worth $371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in RGEN. Vanguard Group Inc. boosted its holdings in shares of Repligen by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after buying an additional 21,719 shares during the period. Brown Capital Management LLC boosted its stake in Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after acquiring an additional 83,416 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after buying an additional 121,305 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 0.0 %

Repligen stock opened at $140.00 on Tuesday. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The stock has a market capitalization of $7.82 billion, a PE ratio of 560.00, a price-to-earnings-growth ratio of 4.20 and a beta of 0.94. The firm has a 50 day simple moving average of $145.84 and a 200-day simple moving average of $156.46.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same period in the prior year, the firm posted $0.53 earnings per share. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. As a group, equities research analysts expect that Repligen Co. will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RGEN. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Guggenheim began coverage on Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. Finally, JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $188.38.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.